SG11201708334RA - Anti-cancer fusion polypeptide - Google Patents
Anti-cancer fusion polypeptideInfo
- Publication number
- SG11201708334RA SG11201708334RA SG11201708334RA SG11201708334RA SG11201708334RA SG 11201708334R A SG11201708334R A SG 11201708334RA SG 11201708334R A SG11201708334R A SG 11201708334RA SG 11201708334R A SG11201708334R A SG 11201708334RA SG 11201708334R A SG11201708334R A SG 11201708334RA
- Authority
- SG
- Singapore
- Prior art keywords
- fusion polypeptide
- cancer fusion
- cancer
- polypeptide
- fusion
- Prior art date
Links
- 230000001093 anti-cancer Effects 0.000 title 1
- 230000004927 fusion Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15166179 | 2015-05-04 | ||
EP15167917 | 2015-05-18 | ||
EP15002702 | 2015-09-17 | ||
EP15192870 | 2015-11-04 | ||
EP16150705 | 2016-01-11 | ||
EP16000862 | 2016-04-15 | ||
PCT/EP2016/060041 WO2016177802A1 (en) | 2015-05-04 | 2016-05-04 | Anti-cancer fusion polypeptide |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201708334RA true SG11201708334RA (en) | 2017-11-29 |
Family
ID=55948826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201708334RA SG11201708334RA (en) | 2015-05-04 | 2016-05-04 | Anti-cancer fusion polypeptide |
Country Status (14)
Country | Link |
---|---|
US (2) | US10865250B2 (ja) |
EP (2) | EP3292148B1 (ja) |
JP (1) | JP6783797B2 (ja) |
KR (1) | KR20170138574A (ja) |
CN (2) | CN107636014B (ja) |
AU (1) | AU2016258977C1 (ja) |
BR (1) | BR112017020434A2 (ja) |
CA (1) | CA2980840A1 (ja) |
HK (1) | HK1249526A1 (ja) |
MX (1) | MX2017014083A (ja) |
RU (1) | RU2727165C2 (ja) |
SG (1) | SG11201708334RA (ja) |
WO (1) | WO2016177802A1 (ja) |
ZA (1) | ZA201705961B (ja) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2936611A1 (en) * | 2014-01-13 | 2015-07-16 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
NZ736560A (en) * | 2015-05-04 | 2021-12-24 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
EP4219535A1 (en) | 2015-05-18 | 2023-08-02 | Pieris Pharmaceuticals GmbH | Anti-cancer fusion polypeptide |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
WO2017220555A1 (en) | 2016-06-20 | 2017-12-28 | F-Star Beta Limited | Lag -3 binding members |
CA3027612A1 (en) | 2016-06-20 | 2017-12-28 | F-Star Delta Limited | Binding molecules binding pd-l1 and lag-3 |
GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
CR20190309A (es) * | 2017-01-03 | 2019-08-21 | Hoffmann La Roche | Moleculas de unión de3 antígeno biespecíficas que comprenden el clon 20h4.9 anti-4-1bb |
GB201700345D0 (en) * | 2017-01-09 | 2017-02-22 | F-Star Beta Ltd | Conditional agonists of immune responses |
WO2018134279A1 (en) * | 2017-01-18 | 2018-07-26 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptides specific for lag-3 and pd-1 |
EP3585431A4 (en) * | 2017-02-24 | 2020-12-16 | MacroGenics, Inc. | BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES |
MY202336A (en) | 2017-07-11 | 2024-04-24 | Compass Therapeutics Llc | Agonist antibodies that bind human cd137 and uses thereof |
US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
CN118667027A (zh) * | 2017-11-13 | 2024-09-20 | 克雷森多生物制剂有限公司 | 结合至cd137和psma的分子 |
WO2019100052A2 (en) | 2017-11-20 | 2019-05-23 | Compass Therapeutics Llc | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
US11548948B2 (en) | 2017-12-19 | 2023-01-10 | F-Star Therapeutics Limited | FC binding fragments comprising a PD-L1 antigen-binding site |
TWI841551B (zh) * | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | 使用靶向4-1bb (cd137)之促效劑的組合療法 |
TW202003462A (zh) | 2018-03-26 | 2020-01-16 | 德商4Sc製藥公司 | 用於癌症療法的包括hdac抑制劑和cd137激動劑之組合 |
CR20200459A (es) * | 2018-04-13 | 2020-11-11 | Hoffmann La Roche | Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl |
GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
US20220049007A1 (en) | 2018-07-12 | 2022-02-17 | F-Star Beta Limited | Antibody molecules that bind pd-l1 and cd137 |
GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
CA3100119A1 (en) * | 2018-07-31 | 2020-02-06 | Pieris Pharmaceuticals Gmbh | Fusion protein specific for cd137 and pd-l1 |
KR20210052468A (ko) * | 2018-08-27 | 2021-05-10 | 피어이스 파마슈티컬즈 게엠베하 | Cd137/her2 이중특이적 제제 및 pd-1 축 억제제를 포함하는 조합물 치료요법 및 이의 용도 |
MA55069A (fr) * | 2019-02-26 | 2022-01-05 | Pieris Pharmaceuticals Gmbh | Nouvelles protéines de fusion spécifique à cd137 et gpc3 |
JP2022526367A (ja) * | 2019-03-29 | 2022-05-24 | ピエリス ファーマシューティカルズ ゲーエムベーハー | リポカリンムテインの吸入投与 |
JP7301155B2 (ja) * | 2019-04-12 | 2023-06-30 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | リポカリンムテインを含む二重特異性抗原結合分子 |
BR112022001336A8 (pt) * | 2019-07-26 | 2023-02-07 | Abl Bio Inc | Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo |
EP4054718A1 (en) | 2019-11-04 | 2022-09-14 | Pieris Pharmaceuticals GmbH | Her2/4-1bb bispecific fusion proteins for the treatment of cancer |
EP4110826A4 (en) * | 2020-02-28 | 2024-08-14 | Shanghai Henlius Biotech Inc | ANTI-CD137 CONSTRUCTS, MULTISPECIFIC ANTIBODIES AND THEIR USES |
WO2022029496A1 (en) * | 2020-08-07 | 2022-02-10 | Eutilex Co., Ltd. | Anti-her2 / anti-4-1bb bispecific antibodies and uses thereof |
EP4213946A1 (en) | 2020-09-18 | 2023-07-26 | Pieris Pharmaceuticals GmbH | Biomarker methods and uses |
KR20220107968A (ko) * | 2021-01-25 | 2022-08-02 | 주식회사유한양행 | 항-4-1bb/항-her2 이중특이적 항체의 정제방법 |
CA3211591A1 (en) | 2021-03-23 | 2022-09-29 | Markus Zettl | Her2/4-1bb bispecific fusion proteins for the treatment of cancer |
WO2022200478A1 (en) | 2021-03-24 | 2022-09-29 | Pieris Pharmaceuticals Gmbh | Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor |
WO2023180523A1 (en) | 2022-03-24 | 2023-09-28 | Pieris Pharmaceuticals Gmbh | Process for purifying fusion proteins |
WO2024085166A1 (ja) * | 2022-10-19 | 2024-04-25 | アステラス製薬株式会社 | がん治療におけるpd-1シグナル阻害剤との組み合わせによる抗cldn4-抗cd137二重特異性抗体の使用 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
ATE76311T1 (de) | 1986-08-19 | 1992-06-15 | Genentech Inc | Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen. |
JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法 |
FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
ES2245780T3 (es) | 1994-05-18 | 2006-01-16 | Nektar Therapeutics | Metodos y composiciones para la formulacion de interferones como un polvo seco. |
DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
AU5132096A (en) | 1995-01-30 | 1996-08-21 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
WO1998016873A1 (fr) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Procede de preparation de dispersions a base de composants chromogenes |
US20030171551A1 (en) | 1997-01-31 | 2003-09-11 | Joseph D. Rosenblatt | Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response |
WO1999007740A2 (en) | 1997-08-06 | 1999-02-18 | Zymogenetics, Inc. | Lipocalin homologs |
US20140080177A1 (en) | 1997-09-26 | 2014-03-20 | Pieris Ag | Anticalins |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
PL192364B1 (pl) | 1998-06-08 | 2006-10-31 | Hoffmann La Roche | Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną |
US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
CA2343917A1 (en) | 1998-10-19 | 2000-04-27 | Ariad Gene Therapeutics, Inc. | Materials and methods involving conditional retention domains |
DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
CA2464690A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
AU2003264100A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of a bilin-binding protein with affinity for a given target |
AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
WO2007038619A2 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
EP2046820B1 (en) * | 2006-08-01 | 2010-10-20 | Pieris AG | Muteins of tear lipocalin and methods for obtaining the same |
EP2235053A1 (en) | 2007-10-19 | 2010-10-06 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
GB2468232B (en) | 2007-11-30 | 2012-10-24 | Glaxo Group Ltd | Antigen-bindng constructs |
EP2262531A1 (en) | 2008-03-08 | 2010-12-22 | Immungene, Inc. | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
AU2009264214B2 (en) * | 2008-06-24 | 2013-06-06 | Technische Universitaet Muenchen | Muteins of hNGAL and related proteins with affinity for a given target |
WO2010097394A1 (en) | 2009-02-24 | 2010-09-02 | Glaxo Group Limited | Multivalent and/or multispecific rankl-binding constructs |
BRPI1013807A2 (pt) | 2009-05-28 | 2019-09-24 | Glaxo Group Ltd | composição, uso de uma composição, antagonista, sequência de polinucleotídeo, célula hospedeira recombinante transformada ou transfectada, método para a produção de uma composição, método para prevenir ou tratar um paciente, molécula de ligação de antígeno de marcação dual, e, proteína de ligação de antígeno. |
IN2012DN00407A (ja) | 2009-08-05 | 2015-08-21 | Pieris Ag | |
EP3660510A3 (en) | 2009-12-07 | 2020-07-08 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
DK2542590T4 (da) * | 2010-03-05 | 2020-07-13 | Univ Johns Hopkins | Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner |
CN103154023B (zh) | 2010-08-16 | 2017-04-05 | 皮里斯制药有限公司 | 铁调素的结合蛋白 |
JP6100694B2 (ja) | 2010-11-15 | 2017-03-22 | ピエリス ファーマシューティカルズ ゲーエムベーハー | グリピカン−3(gpc3)に対して親和性を有するヒトリポカリン2の突然変異タンパク質 |
EP2646552B1 (en) | 2010-12-02 | 2017-07-05 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 with affinity for ctla-4 |
PT3489254T (pt) * | 2012-04-30 | 2022-12-30 | Biocon Ltd | Proteínas de fusão direcionadas/imunomoduladoras e seus métodos de fabrico |
CA2936611A1 (en) | 2014-01-13 | 2015-07-16 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
EA037654B1 (ru) * | 2014-12-30 | 2021-04-27 | Селджин Корпорейшн | Анти-cd47-антитела и их применения |
US11382963B2 (en) | 2015-01-12 | 2022-07-12 | Pieris Pharmaceuticals Gmbh | Engineered T cells and uses therefor |
EP3250586B1 (en) | 2015-01-28 | 2021-10-27 | Pieris Pharmaceuticals GmbH | Novel proteins specific for angiogenesis |
WO2016131804A1 (en) | 2015-02-18 | 2016-08-25 | Sanofi | Novel proteins specific for pyoverdine and pyochelin |
NZ736560A (en) | 2015-05-04 | 2021-12-24 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
BR112017020961A2 (pt) | 2015-05-18 | 2018-07-10 | Pieris Pharmaceuticals Gmbh | muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação |
TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
-
2016
- 2016-05-04 SG SG11201708334RA patent/SG11201708334RA/en unknown
- 2016-05-04 RU RU2017135596A patent/RU2727165C2/ru active
- 2016-05-04 CN CN201680025273.9A patent/CN107636014B/zh active Active
- 2016-05-04 KR KR1020177034820A patent/KR20170138574A/ko not_active Application Discontinuation
- 2016-05-04 CN CN202111366682.4A patent/CN114316067A/zh active Pending
- 2016-05-04 US US15/571,561 patent/US10865250B2/en active Active
- 2016-05-04 WO PCT/EP2016/060041 patent/WO2016177802A1/en active Application Filing
- 2016-05-04 BR BR112017020434A patent/BR112017020434A2/pt active Search and Examination
- 2016-05-04 EP EP16721154.9A patent/EP3292148B1/en active Active
- 2016-05-04 AU AU2016258977A patent/AU2016258977C1/en active Active
- 2016-05-04 EP EP24151494.2A patent/EP4378962A3/en active Pending
- 2016-05-04 CA CA2980840A patent/CA2980840A1/en active Pending
- 2016-05-04 JP JP2017557310A patent/JP6783797B2/ja active Active
- 2016-05-04 MX MX2017014083A patent/MX2017014083A/es unknown
-
2017
- 2017-09-01 ZA ZA2017/05961A patent/ZA201705961B/en unknown
-
2018
- 2018-06-22 HK HK18107992.3A patent/HK1249526A1/zh unknown
-
2020
- 2020-11-12 US US17/096,750 patent/US20210198380A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN114316067A (zh) | 2022-04-12 |
EP4378962A2 (en) | 2024-06-05 |
EP3292148A1 (en) | 2018-03-14 |
AU2016258977A1 (en) | 2017-11-30 |
AU2016258977C1 (en) | 2022-07-14 |
JP2018515085A (ja) | 2018-06-14 |
CA2980840A1 (en) | 2016-11-10 |
JP6783797B2 (ja) | 2020-11-11 |
MX2017014083A (es) | 2018-11-09 |
RU2727165C2 (ru) | 2020-07-21 |
US20210198380A1 (en) | 2021-07-01 |
ZA201705961B (en) | 2023-12-20 |
EP3292148B1 (en) | 2024-01-24 |
BR112017020434A2 (pt) | 2018-06-26 |
KR20170138574A (ko) | 2017-12-15 |
HK1249526A1 (zh) | 2018-11-02 |
CN107636014A (zh) | 2018-01-26 |
WO2016177802A1 (en) | 2016-11-10 |
RU2017135596A3 (ja) | 2019-09-16 |
RU2017135596A (ru) | 2019-06-04 |
EP4378962A3 (en) | 2024-07-31 |
AU2016258977B2 (en) | 2022-03-17 |
CN107636014B (zh) | 2021-12-07 |
US20190010248A1 (en) | 2019-01-10 |
US10865250B2 (en) | 2020-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1249526A1 (zh) | 抗癌融合多肽 | |
ZA201706061B (en) | Anti-cancer fusion polypeptide | |
HK1244019A1 (zh) | 融合蛋白 | |
HK1250041A1 (zh) | 多肽 | |
GB201509413D0 (en) | Fusion protein | |
EP3188758C0 (en) | SIRP-ALPHA ANTIBODY FUSION PROTEINS | |
HK1246316A1 (zh) | 細胞因子融合蛋白 | |
HK1232136A1 (zh) | 融合蛋白 | |
IL253004B (en) | il-17a binding polypeptides | |
GB201504691D0 (en) | Fusion protein | |
HK1250040A1 (zh) | 多肽 | |
SI3390620T1 (sl) | Fuzijske variante polipeptida z izboljšanimi lastnostmi, povezane z omega-hidroksilazo | |
HK1257937A1 (zh) | 融合蛋白 | |
SI3087179T1 (sl) | Fuzijski polipeptidi z izboljšanimi lastnostmi, povezani z omega hidroksilazo | |
SG11201606501PA (en) | Nanobody-fluorescent protein fusion | |
GB201602850D0 (en) | Fusion proteins | |
PT3298030T (pt) | Polipeptídeo de fusão anticancro | |
GB201713537D0 (en) | Fusion Polypeptide | |
GB201503789D0 (en) | Fusion polypeptide | |
GB201502166D0 (en) | Bonding polypeptides |